MOERAE MATRIX

Moerae Matrix is a privately held biopharmaceutical company focused on the development of first-in-class targeted therapeutics for fibrotic disease. Based on proprietary technology from Purdue University, the company is advancing a suite of peptide therapeutics that target MAPKAP kinase 2 (MK2), a key terminal kinase in the TGF-beta/p38 pathway, with a high degree of specificity. Moerae Matrix's first development candidate, MMI-0100, shows excellent activity in multiple models of fibrosis, including the bleomycin model of pulmonary fibrosis, in which MMI-0100 uniquely demonstrates potent anti-fibrotic activity even when administered days after the onset of injury. The compound has an excellent preclinical toxicology profile and is IND-ready for clinical development in acute fibrotic indications. Preclinical development is also underway with a pulmonary delivery formulation of MMI-0100 for chronic treatment of idiopathic pulmonary fibrosis (IPF)... Moerae Matrix is a clinical stage..

Also known as: Moerae Matrix, Inc.

Primary location: Morristown United States